Evidence map›Paper›PMID 36825095›Full record

ArticleCase reports in oncology

Carbon-Ion Radiotherapy Using Metal Artifact Reduction Computed Tomography in a Patient with Prostate Cancer with Bilateral Hip Prostheses: A Case Report.

Yosuke Takakusagi, Yoshiki Takayama, Yohsuke Kusano, Hiroaki Koge, Kio Kano, Satoshi Shima, Keisuke Tsuchida, Nobutaka Mizoguchi, Daisaku Yoshida, Tadashi Kamada and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yosuke TakakusagiaDepartment of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Yoshiki TakayamabSection of Medical Physics and Engineering, Kanagawa Cancer Center, Yokohama, Japan.
Yohsuke KusanobSection of Medical Physics and Engineering, Kanagawa Cancer Center, Yokohama, Japan.
Hiroaki KogeaDepartment of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Kio KanoaDepartment of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Satoshi ShimaaDepartment of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Keisuke TsuchidaaDepartment of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Nobutaka MizoguchiaDepartment of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Daisaku YoshidaaDepartment of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Tadashi KamadaaDepartment of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Shin MiyakawabSection of Medical Physics and Engineering, Kanagawa Cancer Center, Yokohama, Japan.
Koh ImurabSection of Medical Physics and Engineering, Kanagawa Cancer Center, Yokohama, Japan.
Hiroyuki KatohaDepartment of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbon-ion radiotherapy (CIRT) for prostate cancer is both safe and efficacious; beam range calculations use relative stopping power ratio, which is derived from computed tomography (CT) values. However, hip prostheses are made of high atomic number materials and show severe artifacts on CT images. Therefore, it is not possible to accurately calculate dose distribution for CIRT in patients with prostate cancer with hip prostheses. Here, we describe the management of a 77-year-old man with prostate cancer who had previously undergone bilateral hip replacement. CIRT, in combination with androgen deprivation therapy, was recommended as definitive treatment for prostate cancer. Planning CT, magnetic resonance (MRI), and CT images with metal artifact reduction (MAR) were acquired for CIRT planning. MRI and MAR images were superimposed on the planning CT to delineate target volume and organs at risk. The radiation treatment plan consisted of a total dose of 51.6 Gy (relative biological effect) to be delivered in 12 fractions over 3 weeks, and the patient was irradiated in the supine and prone positions with a vertical beam, on alternating days. CIRT was completed as scheduled. No adverse events were observed during treatment or at 3 months after treatment initiation. While we show that CIRT may be a treatment option for patients with prostate cancer with bilateral hip prostheses, further studies are needed to evaluate treatment efficacy and late toxicity and to determine how CIRT can be administered to patients with prostate cancer with bilateral hip prostheses.

Indexed as

Acute toxicityBilateral hip prosthesesCarbon-ion radiotherapyMetal artifact reductionProstate cancer

Identifiers

PMID36825095
PMCPMC9941787

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.